DSI - DS InPharmatics
Colman Byrne has a diverse work experience spanning several companies and roles. Colman started their career at Charles River Labs (Tektagen) in 1990, where they held various positions until 1999. In 2000, they joined Eximias as the Director of Chemistry and remained in that role until 2005. From 2005 to 2008, they worked at Cardiokine Inc as the Director of Chemistry. In 2007, they moved to DSI - Design Space InPharmatics LLC, initially working as the Director of Analytical R&D and later becoming the Head of Analytical Services, a position they currently hold.
Colman Byrne attended Trinity College Dublin from 1978 to 1982. However, no specific information about the degree or field of study was provided.
This person is not in any teams
DSI - DS InPharmatics
DS InPharmatics (DSI) offers one-stop, full-service CMC consulting resources to emerging pharmaceutical and biopharmaceutical companies. The exceptional value DS InPharmatics offers begins with our dedicated, multidisciplinary teams of manufacturing, quality, and regulatory affairs specialists. Our CMC consultants combine in-depth technical knowledge of product development with risk-based submission content and regulatory strategies for all phases of the review and approval process. This breadth of pharmaceutical development expertise provides you with a single, integrated source for efficient problem-solving strategies and scientific expertise. Whether your needs are comprehensive or tightly focused on a specific project, our experienced CMC consultants will help keep your drug development program on track. Not just advice. DSI provides you with hands-on, flexible resources and expanded operational capability, to implement a compliant drug development strategy and timelines. In April 2021 we were thrilled to announce that DSI has just become part of ProductLife Group. Our merger with PLG will harness our combined strengths, offering our clients on both sides of the Atlantic support with their developed drugs approvals and post-approvals compliance, plus advisory services on the best market strategies to deliver a rapid ROI on their development. Together we will offer our clients increased pharmacovigilance capabilities - including a QPPV; pharmacovigilance consulting; and a fully validated safety database – as well as complementary toxicology-related services; RIM/electronic document management services; and support for medical device regulatory requirements. We see enormous potential in this new chapter for DSI and for you, our clients. As a PLG company, we have the opportunity to become part of a global force in life sciences regulatory and compliance solutions and services, and we’re incredibly excited to add our momentum to that effort.